🔗 Share this article

While the US proceeds with unprecedented adjustments to its vaccine guidelines, one figure has emerged unexpectedly: Tracy Beth Høeg, a US-based sports medicine doctor and public health researcher who rose to prominence by expressing skepticism about coronavirus vaccinations in the pandemic and has concentrated on potential deaths after COVID-19 immunization in her brief tenure at the FDA.

Proposed Overhauls to Pediatric Immunization Schedule

Health officials planned to unveil radical revisions to the pediatric immunization program recently, aligning the US with the Danish immunization schedule, it is understood – a substantial departure that would place the US at odds with many the global community with insufficient data for public health gain. The announcement has been pushed back until the next year.

Instead of the top vaccines chief, Høeg is listed to present at the event. She was newly appointed acting director of the FDA’s drug evaluation center, the fifth person to run the office this year.

A New Direction at the Regulatory Body

This interim role might represent a closer partnership between the drug and biologics centers as Dr. Høeg and Dr. Prasad consolidate power at the regulatory agency – and it suggests a renewed priority upon dismantling long-standing immunizations at the FDA.

Dr. Høeg has often pushed for discontinuing certain pediatric immunization guidelines in the US in order to be more like the Danish model, a country with universal health coverage and a number of inhabitants roughly the population of the state of Wisconsin.

To date statements, she has persisted in emphasizing on immunizations – traditionally the purview of Prasad, head of the FDA’s vaccine center – instead of drug regulation.

Questions Over Background

Høeg has no obvious experience in drug development, oversight or management, which has been typical for past leaders of the biologics center. She has served at the FDA as a senior adviser to the commissioner and the vaccine center since March.

“She appears not to have any of the qualifications” for overseeing the drug-regulation department, remarked Jonathan Howard. “She’s never run a clinical trial. She is not versed in managing a major agency. She has no expertise in pharmaceutical oversight.”

Former commissioners of the center would “be deeply familiar with laws and regulations and the research of pharmaceutical innovation”, commented Janet Woodcock. “Objectively, she doesn’t have the sort of resume that former directors who headed CBER have had.”

The drug center has an immense portfolio at the FDA, the former commissioner stated.

“The public just pays attention on the novel medication approvals, but the off-patent medication office authorizes numerous generic drugs. There’s a biosimilars program, over-the-counter program and so forth, and every single one have to be supervised,” Woodcock said. “The area you neglect, that is the part that I always told people is going to come back to haunt you.”

Furthermore, a major leadership component to the job, which oversees more than 5,000 employees. “It is a enormous administrative position, if you do it right,” Woodcock said.

Official Statement and Disputed Programs

When asked about questions about Høeg’s credentials and whether this selection indicates increased cooperation among FDA leaders on immunizations, a representative said that the “questions are based on incorrect presumptions”.

“This background is consistent with the duties of her position,” the official stated, citing the time Høeg spent counseling the agency head on “medication safety and regulatory science, including computerized risk analysis and immunization monitoring”.

In her interim role, Dr. Høeg assumes responsibility for the agency head's recently launched priority voucher program, a disputed expedited medication authorization process that apparently worried her former heads. “How are these drugs being selected for this voucher program? Who takes the calls?” Dr. Howard said. “There is a lot of lack of transparency occurring at the FDA right now.”

Overall, he said, “the Food and Drug Administration looks to be trending towards laxer oversight of most medications, aside from vaccines.”

Established Past Work on Immunizations

Regarding immunizations, Høeg has a clearer, if problematic, past, critics observe. She published a research paper using unverified volunteer-provided data to determine the frequency of myocarditis following COVID-19 immunization. She counseled the state of Florida top health official Dr. Joseph Ladapo, who reportedly have changed statistics to indicate Covid vaccines are pose a greater threat than they are.

Included in her “desired changes” for the new federal leadership featured altering rules for novel immunizations and ending “unnecessary” vaccines, she stated following the vote on a podcast. At the agency, Dr. Høeg has reportedly suggested excluding adolescent males from obtaining COVID-19 vaccinations.

“She’s an complete dogmatist who starts off with her beliefs and tailors the evidence to fit the science in a very disingenuous, dishonest fashion,” Howard argued.

Gaining Influence and a “Push for Payback”

Dr. Høeg became part of other contrarians, {like|